Contraindicated (1)bortezomib will boost the degree or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or average CYP2C19 inhibitors may boost mavacamten systemic publicity, causing coronary heart failure due to systolic dysfunction. Acute enhancement or exacerbation of congestive coronary heart failure and new onset of reduced still https://damienfcumz.blogsidea.com/32889371/the-smart-trick-of-verteporfin-that-nobody-is-discussing